ABBOTT LABORATORIES — Director's Dealing 2021

Feb 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-02-19

Reporting Person: Moreland Mary K (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-19	Common shares without par value	A	13513	—	Acquired	76886	Direct
2021-02-22	Common shares without par value	F	780	$123.04	Disposed	76106	Direct
2021-02-22	Common shares without par value	S	400	$121.835	Disposed	75706	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-19	Option (right to buy)	$124.04	A	69266	Acquired	2031-02-18	Common Shares (69266)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	10826	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 19, 2021.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,088 on February 19, 2022, 23,089 on February 19, 2023, and 23,089 on February 19, 2024.